高凤凤, 裴艳玲, 任越, 陈紫军, 卢建秋, 张燕玲. 基于网络药理学与分子对接技术研究黄精抗动脉粥样硬化的作用机制J. 药学学报, 2020,55(11): 2642-2650. doi: 10.16438/j.0513-4870.2020-0299
引用本文: 高凤凤, 裴艳玲, 任越, 陈紫军, 卢建秋, 张燕玲. 基于网络药理学与分子对接技术研究黄精抗动脉粥样硬化的作用机制J. 药学学报, 2020,55(11): 2642-2650. doi: 10.16438/j.0513-4870.2020-0299
GAO Feng-feng, PEI Yan-ling, REN Yue, CHEN Zi-jun, LU Jian-qiu, ZHANG Yan-ling. Possible mechanisms by which Polygonati rhizoma opposes atherosclerosis based on network pharmacology and molecular docking analysesJ. Acta Pharmaceutica Sinica, 2020,55(11): 2642-2650. doi: 10.16438/j.0513-4870.2020-0299
Citation: GAO Feng-feng, PEI Yan-ling, REN Yue, CHEN Zi-jun, LU Jian-qiu, ZHANG Yan-ling. Possible mechanisms by which Polygonati rhizoma opposes atherosclerosis based on network pharmacology and molecular docking analysesJ. Acta Pharmaceutica Sinica, 2020,55(11): 2642-2650. doi: 10.16438/j.0513-4870.2020-0299

基于网络药理学与分子对接技术研究黄精抗动脉粥样硬化的作用机制

Possible mechanisms by which Polygonati rhizoma opposes atherosclerosis based on network pharmacology and molecular docking analyses

  • 摘要: 利用网络药理学和分子对接技术从整体层面阐释黄精治疗动脉粥样硬化(atherosclerosis,AS)的作用机制。通过中药化学成分数据库(TCMD)和中药系统药理学数据库(TCMSP)收集黄精化学成分并利用PharmaDB、Swiss TargetPrediction预测其作用靶点集,借助OMIM、DisGeNET及NCBI基因数据库检索AS相关靶点集。取两靶点集交集获取黄精治疗AS的潜在作用靶点,基于STRING平台构建交集靶点相互作用网络并在Cytoscape中进行可视化分析。根据拓扑参数筛选黄精治疗AS的关键靶点,采用Clue GO对交集靶点进行GO和KEGG富集分析。最后利用Discovery Studio 4.0对关键靶点进行分子对接验证。结果筛选获得45个黄精活性成分和51个黄精治疗AS的潜在作用靶点,拓扑分析结果包含的5个关键靶点为血清白蛋白、丝裂原活化蛋白激酶3、丝裂原活化蛋白激酶1、原癌基因酪氨酸蛋白激酶Src和基质金属蛋白酶-9。GO富集分析得到131个GO条目,主要涉及类固醇激素受体的活性、细胞对类固醇激素刺激的反应和磷脂酰肌醇-3激酶信号通路等生命过程。KEGG通路分析得到37条主要信号通路,主要涉及过氧化物酶体增殖激活受体信号通路、血小板激活信号通路、血管内皮生长因子信号通路、低氧诱导因子信号通路和黏着连接信号通路。分子对接结果显示,黄精成分与潜在关键靶点具有较好的结合活性。本研究从网络药理学的角度初步阐释了黄精治疗动脉粥样硬化的作用机制,旨在为其进一步的临床研究提供科学依据。

     

    Abstract: Possible mechanisms by which Polygonati rhizoma opposes atherosclerosis (AS) were identified by network pharmacology and molecular docking analyses. The Traditional Chinese Medicine Database (TCMD) and the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) were utilized to identify the likely active components of Polygonati rhizoma. The potential targets set of Polygonati rhizoma were predicted with the PharmaDB database and the Swiss TargetPrediction database. The targets set for AS was retrieved by OMIM, DisGeNET and NCBI Gene database. We used the STRING platform to construct a protein-protein interaction network of the intersectional targets and performed visual analysis in Cytoscape. The key targets of Polygonati rhizoma in AS were searched by network topology and the resulting GO and KEGG enrichment was analyzed by Clue GO. In addition, the key targets were verified by molecular docking in Discovery Studio 4.0. A total of 45 active ingredients and 51 potential targets were obtained in the treatment of AS. The results of the topology analysis included five key targets:serum albumin, mitogen-activated protein kinase 3, mitogen-activated protein kinase 1, proto-oncogene tyrosine-protein kinase Src and matrix metalloproteinase-9. The 131 GO items showed that the biological process mainly involved the steroid receptor, cell response to steroid stimulation, the phosphatidylinositol-3 kinase signal pathway, and others. The KEGG pathway analysis included 37 pathways, which were closely related to peroxisome proliferation activated receptor signaling pathway, platelet activation pathway, vascular endothelial growth factor pathway, hypoxia inducible factor pathway and adhesion connection pathway. The results of molecular docking proved that the combined activity of the components with potential key targets is excellent. This study proposes mechanisms by which Polygonati rhizoma might act to reverse or minimize AS and provides a scientific basis for clinical research on Polygonati rhizoma.

     

/

返回文章
返回